Cargando…

MRS-guided HDR brachytherapy boost to the dominant intraprostatic lesion in high risk localised prostate cancer

BACKGROUND: It is known that the vast majority of prostate cancers are multifocal. However radical radiotherapy historically treats the whole gland rather than individual cancer foci. Magnetic resonance spectroscopy (MRS) can be used to non-invasively locate individual cancerous tumours in prostate....

Descripción completa

Detalles Bibliográficos
Autores principales: Kazi, Aleksandra, Godwin, Guy, Simpson, John, Sasso, Giuseppe
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2941503/
https://www.ncbi.nlm.nih.gov/pubmed/20809986
http://dx.doi.org/10.1186/1471-2407-10-472
_version_ 1782186911571378176
author Kazi, Aleksandra
Godwin, Guy
Simpson, John
Sasso, Giuseppe
author_facet Kazi, Aleksandra
Godwin, Guy
Simpson, John
Sasso, Giuseppe
author_sort Kazi, Aleksandra
collection PubMed
description BACKGROUND: It is known that the vast majority of prostate cancers are multifocal. However radical radiotherapy historically treats the whole gland rather than individual cancer foci. Magnetic resonance spectroscopy (MRS) can be used to non-invasively locate individual cancerous tumours in prostate. Thus an intentionally non-uniform dose distribution treating the dominant intraprostatic lesion to different dose levels than the remaining prostate can be delivered ensuring the maximum achievable tumour control probability. The aim of this study is to evaluate, using radiobiological means, the feasibility of a MRS-guided high dose rate (HDR) brachytherapy boost to the dominant lesion. METHODS: Computed tomography and MR/MRS were performed for treatment planning of a high risk localised prostate cancer. Both were done without endorectal coil, which distorts shape of prostate during the exams. Three treatment plans were compared: - external beam radiation therapy (EBRT) only - combination of EBRT and HDR brachytherapy - combination of EBRT and HDR brachytherapy with a synchronous integrated boost to the dominant lesion The criteria of plan comparison were: the minimum, maximum and average doses to the targets and organs at risk; dose volume histograms; biologically effective doses for organs at risk and tumour control probability for the target volumes consisting of the dominant lesion as detected by MR/MRS and the remaining prostate volume. RESULTS: Inclusion of MRS information on the location of dominant lesion allows a safe increase of the dose to the dominant lesion while dose to the remaining target can be even substantially decreased keeping the same, high tumour control probability. At the same time an improved urethra sparing was achieved comparing to the treatment plan using a combination of EBRT and uniform HDR brachytherapy. CONCLUSIONS: MRS-guided HDR brachytherapy boost to dominant lesion has the potential to spare the normal tissue, especially urethra, while keeping the tumour control probability high.
format Text
id pubmed-2941503
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-29415032010-09-21 MRS-guided HDR brachytherapy boost to the dominant intraprostatic lesion in high risk localised prostate cancer Kazi, Aleksandra Godwin, Guy Simpson, John Sasso, Giuseppe BMC Cancer Technical Advance BACKGROUND: It is known that the vast majority of prostate cancers are multifocal. However radical radiotherapy historically treats the whole gland rather than individual cancer foci. Magnetic resonance spectroscopy (MRS) can be used to non-invasively locate individual cancerous tumours in prostate. Thus an intentionally non-uniform dose distribution treating the dominant intraprostatic lesion to different dose levels than the remaining prostate can be delivered ensuring the maximum achievable tumour control probability. The aim of this study is to evaluate, using radiobiological means, the feasibility of a MRS-guided high dose rate (HDR) brachytherapy boost to the dominant lesion. METHODS: Computed tomography and MR/MRS were performed for treatment planning of a high risk localised prostate cancer. Both were done without endorectal coil, which distorts shape of prostate during the exams. Three treatment plans were compared: - external beam radiation therapy (EBRT) only - combination of EBRT and HDR brachytherapy - combination of EBRT and HDR brachytherapy with a synchronous integrated boost to the dominant lesion The criteria of plan comparison were: the minimum, maximum and average doses to the targets and organs at risk; dose volume histograms; biologically effective doses for organs at risk and tumour control probability for the target volumes consisting of the dominant lesion as detected by MR/MRS and the remaining prostate volume. RESULTS: Inclusion of MRS information on the location of dominant lesion allows a safe increase of the dose to the dominant lesion while dose to the remaining target can be even substantially decreased keeping the same, high tumour control probability. At the same time an improved urethra sparing was achieved comparing to the treatment plan using a combination of EBRT and uniform HDR brachytherapy. CONCLUSIONS: MRS-guided HDR brachytherapy boost to dominant lesion has the potential to spare the normal tissue, especially urethra, while keeping the tumour control probability high. BioMed Central 2010-09-01 /pmc/articles/PMC2941503/ /pubmed/20809986 http://dx.doi.org/10.1186/1471-2407-10-472 Text en Copyright ©2010 Kazi et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Technical Advance
Kazi, Aleksandra
Godwin, Guy
Simpson, John
Sasso, Giuseppe
MRS-guided HDR brachytherapy boost to the dominant intraprostatic lesion in high risk localised prostate cancer
title MRS-guided HDR brachytherapy boost to the dominant intraprostatic lesion in high risk localised prostate cancer
title_full MRS-guided HDR brachytherapy boost to the dominant intraprostatic lesion in high risk localised prostate cancer
title_fullStr MRS-guided HDR brachytherapy boost to the dominant intraprostatic lesion in high risk localised prostate cancer
title_full_unstemmed MRS-guided HDR brachytherapy boost to the dominant intraprostatic lesion in high risk localised prostate cancer
title_short MRS-guided HDR brachytherapy boost to the dominant intraprostatic lesion in high risk localised prostate cancer
title_sort mrs-guided hdr brachytherapy boost to the dominant intraprostatic lesion in high risk localised prostate cancer
topic Technical Advance
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2941503/
https://www.ncbi.nlm.nih.gov/pubmed/20809986
http://dx.doi.org/10.1186/1471-2407-10-472
work_keys_str_mv AT kazialeksandra mrsguidedhdrbrachytherapyboosttothedominantintraprostaticlesioninhighrisklocalisedprostatecancer
AT godwinguy mrsguidedhdrbrachytherapyboosttothedominantintraprostaticlesioninhighrisklocalisedprostatecancer
AT simpsonjohn mrsguidedhdrbrachytherapyboosttothedominantintraprostaticlesioninhighrisklocalisedprostatecancer
AT sassogiuseppe mrsguidedhdrbrachytherapyboosttothedominantintraprostaticlesioninhighrisklocalisedprostatecancer